Wilson disease
Oct. 23, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Isovaleric acidemia
- Updated 04.30.2024
- Released 09.22.2003
- Expires For CME 04.30.2027
Isovaleric acidemia
Introduction
Overview
In this article, the author describes the different manifestations of this inborn error of leucine catabolism and explains disease diagnosis and treatment. Opportunities and challenges of extended newborn screening programs are discussed; patients identified early through newborn screening have a highly improved prognosis, and a newly recognized subcohort may have a mild or even asymptomatic clinical course.
Key points
|
• Isovaleric aciduria due to isovaleryl-CoA dehydrogenase deficiency presents with two distinct phenotypes: (1) acute neonatal onset with severe metabolic crisis that, without appropriate treatment, quickly evolves into coma and death or (2) a chronic intermittent disease with episodes of metabolic acidosis and psychomotor retardation. | |
|
• Key metabolites leading to diagnosis are isovalerylglycine in urine and isovaleryl carnitine in plasma or dried blood spots. | |
|
• Treatment must be supervised by an experienced metabolic center and must continue for life. Special care must be taken to ensure efficient emergency procedures at all times (including travel and holidays). | |
|
• Isovaleric acidemia can be readily diagnosed in newborn screening programs | |
|
• If treatment is initiated before the development of severe metabolic decompensation, the patient’s prognosis is significantly improved. Patients who are diagnosed by newborn screening usually have normal psychomotor development. | |
|
• Patients identified by newborn screening who carry the common mutation (A282V, 932C> T) are asymptomatic and most likely do not need treatment. |
Historical note and terminology
Isovaleric acidemia is caused by a deficiency of isovaleryl-CoA dehydrogenase, an enzyme located proximally in the catabolic pathway of the essential branched-chain amino acid leucine.
The disease may manifest in the neonatal period with a severe metabolic crisis that without appropriate treatment quickly evolves into coma and death. Alternatively, patients may have a chronic intermittent disease with episodes of metabolic acidosis. The key metabolites leading to diagnosis are isovalerylglycine in urine and isovaleryl carnitine in plasma.
The first description of the clinical and biochemical phenotype was made by Japanese-American geneticist Kay Tanaka (1929-1975) and colleagues (61; 03), making isovaleric acidemia the first recognized organic acid disorder. The identification of the specific enzyme isovaleryl-CoA dehydrogenase was challenging because it was unclear whether a distinct enzyme existed for the degradation of isovaleryl-CoA or whether a common enzyme accomplished both the degradation of short-chain acyl-CoA esters in fatty acid oxidation and isovaleryl-CoA in leucine catabolism.
Tanaka and colleagues hypothesized the existence of a dehydrogenase specific for isovaleryl-CoA because of the distinct elevation of isovaleryl metabolites in the absence of elevations of other short-chain acids. In 1980, Rhead and Tanaka proved that this assumption was correct (53). In contrast to normal activity of butyryl-CoA dehydrogenase, deficient activity of isovaleryl-CoA dehydrogenase was demonstrated in fibroblasts of a patient with isovaleric acidemia. Human isovaleryl-CoA dehydrogenase was isolated from liver tissue in 1987 (17). The gene was mapped to chromosome 15q14-q15 (60; 51). Several different mutations causing isovaleric acidemia have subsequently been identified (65).
Clinical manifestations
Presentation and course
|
• Isovaleric aciduria due to isovaleryl-CoA dehydrogenase deficiency presents with two different clinical phenotypes: (1) an acute neonatal-onset form and (2) an infantile chronic-intermittent form. | |
|
• A common mutation (932C-T; A282V) is associated with a mild, usually asymptomatic phenotype but is nevertheless identified by newborn screening. | |
|
• During metabolic crises, patients develop the typical features of an organic acid disorder with acidosis, ketosis, vomiting, progressive alteration of consciousness, and, without appropriate therapy, overwhelming illness, deep coma, and death. |
Isovaleric aciduria due to isovaleryl-CoA dehydrogenase deficiency presents with two different clinical phenotypes: (1) an acute neonatal-onset form, which results in profound metabolic acidosis from the first days of life and rapid death (50; 48), and (2) a chronic infantile form with periodic attacks of severe ketoacidosis interspersed with asymptomatic periods (61; 48). Analogous to methylmalonic aciduria and propionic aciduria, the clinical phenotypes of isovaleric acidemia can be considered early (ie, neonatal) disease onset and late (ie, after the newborn period) disease onset groups (62; 48).
Approximately half of the cases present with acute neonatal onset and the other half with chronic intermittent disease (58). Both phenotypes can occur in populations or even within the same family carrying the same mutation (58; 07; 22). In addition, a common mutation is associated with a mild, usually asymptomatic phenotype. Patients carrying this mutation are nevertheless identified by newborn screening. Molecular genetic analysis within this group identifies around 50% of mutant alleles as the single mutation (932C-T; A282V). This mutation is also found in older, healthy siblings but not in previously identified symptomatic patients; thus, this mutation is associated with a usually asymptomatic clinical course (12).
Children are usually born at term after an uneventful pregnancy. If clinical abnormalities develop within the first days of life, patients refuse feeding, start to vomit, and become progressively dehydrated and lethargic. Hypothermia, developmental delay, intellectual disability or impaired cognition, autism spectrum disorder, movement disorder (tremor, dysmetria, extrapyramidal movements), twitching, seizures, and optic atrophy can occur (30; 55; 42; 48). Other possible clinical findings include a foul odor reminiscent of “sweaty feet” (caused by isovaleric acid).
Acute metabolic decompensation may be triggered by fasting, febrile illness (eg, gastroenteritis), or increased protein intake (48). During metabolic crises, patients develop the typical features of an organic acid disorder with acidosis, ketosis, vomiting, progressive alteration of consciousness, and, finally, without appropriate therapy, overwhelming illness, deep coma, and death (58; 48). Acute metabolic decompensation can quickly lead to death triggered by cerebral edema, intracerebral hemorrhage, or infection. Neuropathological examination shows cerebellar edema with herniation and spongiform changes in the white matter.
In the chronic intermittent form of isovaleric acidemia, children have recurrent metabolic crises because of high intake of protein or minor infections that induce a catabolic state (58). The metabolic crises are characterized by vomiting, lethargy, coma, acidosis, ketosis, and the odor of “sweaty feet.” Some patients develop a dislike of food with a high protein content, apparently an acquired aversion.
Pancreatitis may be a complication of acute and chronic isovaleric aciduria (41). With age, children become less sensitive to minor infections. Older patients may have normal psychomotor development or a wide range of intellectual disability, depending on the frequency and severity of metabolic decompensations, the age at diagnosis, and timing of therapy initiation.
In contrast to other organic acidopathies, such as propionic acidemia or methylmalonic academia, there is no apparent disease progression or multisystemic organ dysfunction.
The disorder may rarely present with a first acute metabolic decompensation in adulthood (16).
Prognosis and complications
Clinical and neurocognitive outcomes in isovaleric acidemia patients depend on early diagnosis and treatment.
In the first reports, isovaleric acidemia was associated with a poor prognosis; more than half of the patients with acute neonatal onset did not survive the first episode, but with improvement in therapy (ie, by supplementation of glycine and L-carnitine) as well as earlier diagnosis, the outcome has become much more favorable (58). In particular, if treatment can be initiated before a first severe metabolic decompensation, the patient’s prognosis is significantly improved. Individuals who receive treatment before becoming symptomatic usually have normal long-term psychomotor development (37).
In a review of 21 symptomatic isovaleric acidemia patients diagnosed as children or adults between 1976 and 1999, 44% had mild motor disfunction, and only 19% had cognitive deficits (19). IQ was not related to the number of metabolic decompensations but was inversely related to the age at diagnosis. One patient died at 13 days of age. Age at evaluation of the remaining patients ranged from 2.2 years to 25.3 years, with a median of 11.2 years. In contrast to the high neonatal mortality (33%) in 155 published cases, only one patient of the study cohort died due to metabolic decompensation in the neonatal period (5%). Results from the European registry and network for Intoxication-type Metabolic Diseases (E-IMD) confirm that clinical and neurocognitive outcomes depend on early diagnosis and treatment (21).
Patients identified by newborn screening who carry a common missense mutation c.932C>T (p.Ala282Val) are usually asymptomatic and most likely do not need treatment. Siblings of these individuals who have the same genotype may remain asymptomatic during episodes of febrile illnesses without any specific treatment (12; 64; 37).
Clinical vignette
A 6-year-old girl was admitted to the hospital with a 3-day history of persistent vomiting but had neither fever nor diarrhea. She was severely dehydrated, drowsy, and hallucinative and had a peculiar fetor like “sweaty feet” but no focal neurologic deficits.
She had previously experienced eight similar episodes associated with prominent metabolic acidosis, which resolved with glucose infusion. She insisted on taking her meals regularly and preferred fruits and vegetables but avoided dairy products and meat. Her somatic and cognitive development had been normal, and she attended primary school with good success. Her family history was unremarkable.
Laboratory investigations revealed severe metabolic acidosis and ketosis. A serum ammonia level was normal. Urine studies showed massive ketonuria and lactaturia as well as highly elevated excretion of both 3-hydroxy isovaleric acid and isovalerylglycine, which established her diagnosis of isovaleric acidemia.
Her severe metabolic acidosis was treated with a single dose of sodium bicarbonate, and she was also treated with high-dose intravenous glucose and carnitine. She recovered completely.
On any ongoing basis, she was treated with a mild protein restriction (which in any case reflected her preferred food pattern), and carnitine supplementation. The family also received an emergency card and a sick-day nutrition plan, which contained high-energy, low-protein food. In case of illness, her carnitine dosage was doubled.
Biological basis
Etiology and pathogenesis
|
• Isovaleric acidemia is an inborn error of leucine metabolism that results from deficiency of the mitochondrial enzyme isovaleryl-CoA dehydrogenase, which is caused by a homozygous mutation in the isovaleryl CoA dehydrogenase gene on chromosome 15q15.1. | |
|
• Isovaleric acidemia is transmitted as an autosomal recessive trait. | |
|
• Both clinical presentations, acute-neonatal and infantile chronic-episodic, may be found within the same family and, thus, are determined by other genes or nongenetic factors. | |
|
• Due to the metabolic block, isovaleryl-CoA accumulates, and the pathognomonic metabolite isovalerylglycine is formed by conjugation of isovaleryl-CoA to the amino group of glycine. |
Isovaleric acidemia is an inborn error of leucine metabolism that results from deficiency of the mitochondrial enzyme isovaleryl-CoA dehydrogenase (MIM 243500; EC 1.3.99.10), which is caused by a homozygous mutation in the isovaleryl CoA dehydrogenase gene (IVD; OMIM 607036) on chromosome 15q15.1.
Genetics. Isovaleric acidemia is transmitted as an autosomal recessive trait. The gene coding for isovaleryl-CoA dehydrogenase was mapped by southern blot analysis to chromosome 15q14-q15 (31). Subsequent studies have localized the gene to chromosome 15q1. The 172 kDa enzyme is a tetramer of four identical subunits.
The molecular basis was investigated in detail, and various mutations have been described, including missense mutations, an in-frame mutation, and point mutations leading to abnormal splicing and altered mitochondrial import (43; 66; 65; 67; 35; 25; 36; 06). Genetic complementation studies point to involvement of a single genetic locus (10).
Both clinical presentations, acute-neonatal and infantile chronic-episodic, may be found within the same family and, thus, are determined by other genes or nongenetic factors.
The four identical subunits of isovaleryl-CoA dehydrogenase are synthesized on cytosolic polysomes and imported into the mitochondrial matrix where the enzyme is assembled. The finished enzyme is situated in the inner layer of the mitochondrial membrane. It is a flavin enzyme containing ca. 1 mol FAD/subunit. The FAD transports electrons via coenzyme Q to the respiratory chain.
Pathophysiology. Due to the metabolic block, isovaleryl-CoA accumulates, and the pathognomonic metabolite isovalerylglycine is formed by conjugation of isovaleryl-CoA to the amino group of glycine.
The hydrolysis product isovaleric acid is quantitatively less important. The mitochondrial enzyme that had been thought to catalyze this reaction is glycine N-acyltransferase (GLYAT; glycine-N-acylase; EC 2.3.1.13). However, GLYAT and a paralogue, GLATL1, both form N-isovaleryglycine albeit at lower affinities than their preferred substrates (32). Isovalerylglycine is nontoxic and can be secreted via urine. This reaction is an important detoxification pathway, which can be therapeutically augmented.
The mechanism of isovaleric acid toxicity remains unclear, though it is likely to be multifactorial. Some findings point to an inhibition of mitochondrial energy metabolism (40; 38). One study demonstrated reduced glutathione levels (an indicator of oxidative stress) in a cohort of 11 patients (54). In bone marrow cell cultures, isovaleric acid is an inhibitor of granulopoietic progenitor cell proliferation, which may explain why neutropenia is frequently seen in isovaleric acidemia during metabolic decompensation (58). In addition, amino-acid depletion may be induced by abnormal amino-acid conjugation combined with protein restriction (39), resulting in impaired protein synthesis, catabolic metabolic decompensation, failure to thrive, and additional nutritional insufficiencies (71; 08; 15).
Epidemiology
|
• The worldwide incidence of isovaleric acidemia is 1:100,000 live births diagnosed by newborn screening and 1:280,000 among cases diagnosed after the onset of symptoms. |
Selective screening by analysis of organic acids in urine or tandem mass spectrometry has demonstrated the presence of isovaleric acidemia in different populations around the world (26; 69; 33; 63). In countries where isovaleric acidemia is not part of population newborn screening, the diagnosis can be missed. Reported cases to date do not suggest an ethnic predisposition.
In a systematic review and meta-analysis, 22 population studies of isovaleric acidemia were identified, 17 of which utilized tandem mass spectrometry with a total population screened of 14,304,075, and five of which relied on clinical ascertainment of cases with a total population screened of 5,100,705 (44). The point estimate (and 95% confidence interval) of incidence was 0.36 (0.08 to 1.61) per 100,000 live births worldwide for studies that relied on clinical ascertainment of cases. In contrast, the incidence was 0.79 (0.55-1.13) per 100,000 live births for studies in Western countries and 0.96 (0.63 to 1.45) per 100,000 live births worldwide for studies that relied on tandem mass spectroscopy. In summary, the worldwide incidence of isovaleric acidemia is 1:100,000 live births diagnosed by newborn screening and 1:280,000 among cases diagnosed after the onset of symptoms. Sensitivity was clearly improved using newborn screening approaches with tandem mass spectrometry. (Note: there is a typo in the point estimate for Western countries in the original study, based both on a comparison of the graphed values and the printed numbers and on comparison of the erroneously written value, which is considerably less than the lower bound of the 95% confidence interval.)
Prevention
|
• Isovaleric acidemia can be easily diagnosed in newborn screening programs. | |
|
• If treatment is initiated before the development of severe metabolic decompensation, the patient’s prognosis can be significantly improved. | |
|
• Patients who are diagnosed by newborn screening usually have normal psychomotor development. | |
|
• Prenatal diagnosis is possible in families at risk. |
Isovaleric acidemia can be easily diagnosed in newborn screening programs with electrospray tandem mass spectrometry. For neonates with a positive newborn screening result for isovaleric acidemia, the aim is to provide necessary treatment immediately, while adjusting the treatment to the individual severity of the disease (47).
Since the UK initiated newborn screening for isovaleric acidemia in 2015, changes in prescribing have increased the incidence of false positive results due to pivaloylcarnitine (05). Implementation of dual cut-off values into the screening algorithm reduced the frequency of false positives, with initial C5 carnitine results of 5 μmol/L or greater triggering urgent referral, and those more than 2.0 μmol/L and less than 5.0 μmol/L prompting second-tier C5-isobar testing. This approach avoided delayed referral in high-risk babies while reducing the false positive rate for the rest.
If treatment is initiated before the development of severe metabolic decompensation, the patient’s prognosis can be significantly improved. Patients who are diagnosed by newborn screening usually have normal psychomotor development (37). Unfortunately, in the absence of newborn detection, there is often a marked delay in diagnosis, which may have serious adverse consequences for affected children (25).
Once IVD pathogenic variants have been identified in an affected individual, biochemical or molecular genetic testing of all at risk siblings (of any age) is warranted to allow early diagnosis and treatment of classic isovaleric acidemia (48). Carrier testing for at risk relatives and prenatal and preimplantation genetic testing are possible (48).
Differential diagnosis
Confusing conditions
The catabolic pathway for leucine comprises six enzymes, all of which are associated with recognized inherited deficiencies: (1) isovaleryl-CoA dehydrogenase, deficient in isovaleric acidemia, and producing increased concentrations of hydroxyisovaleric acid and other metabolites; (2) branched-chain alpha-keto acid dehydrogenase, deficient in maple syrup urine disease; (3) 3-methylcrotonyl-CoA carboxylase, deficient in methylcrotonylglycinuria; (4) dehydrogenase; (5) propionyl-CoA carboxylase, deficient in propionic acidemia; and (6) methylmalonyl CoA mutase, deficient in methylmalonic aciduria.
The clinical symptoms and predilection for acute metabolic decompensation in isovaleryl-CoA dehydrogenase deficiency occur also in other organic acid disorders (eg, methylmalonic acidemia and propionic acidemia), fatty acid oxidation disorders, or urea cycle disorders (even the suggestive “odor of sweaty feet” is shared by some other disorders) (30). Classical organic acidemias result from defective mitochondrial catabolism of branched-chain amino acids: isovaleric acidemia, methylmalonic acidemia, and propionic acidemia. Compared to those with methylmalonic acidemia and propionic acidemia, individuals with isovaleric acidemia appear to have a less severe disease course (62). Impaired catabolism of branched-chain amino acids in propionic acidemia, but not in methylmalonic acidemia or isovaleric acidemia, is associated with a metabolic syndrome-like phenotype with abdominal adiposity potentially resulting from ectopic lipid storage (18).
Organic acidopathies can best be differentiated by the specific patterns of nonvolatile urinary organic acids on gas chromatography-mass spectrometry (24).
If vomiting in infancy becomes prominent, hypertrophic pyloric stenosis may be suspected, and patients with isovaleric acidemia have undergone unneeded and potentially risky surgery, especially given their predilection for profound metabolic decompensation (03; 34).
The combination of ketoacidosis, dehydration, and hyperglycemia in patients with isovaleric acidemia has also been misjudged as diabetic ketoacidosis (13).
Diagnostic workup
|
• Diagnosis of classic isovaleric acidemia is established in a proband by (1) identification of C5-carnitine metabolites by tandem mass spectrometry and isovalerylglycine (IVG) and 3-hydroxyisovaleric acid (3-HIVA) on analysis of urinary organic acids by gas chromatography-mass spectrometry, or (2) identification of biallelic pathogenic variants in IVD by molecular genetic testing. | |
|
• During metabolic decompensation, the urinary organic acid profile reveals high excretion of isovalerylglycine (2000 to 9000 mmol/mol creatinine), which remains markedly elevated after recompensation (1000 to 3000 mmol/mol creatinine). | |
|
• The acylcarnitine profile in isovaleric aciduria is characterized by high levels of isovalerylcarnitine, depending on the quantity of oral carnitine administration. |
Neuroimaging. Following a severe metabolic decompensation, cranial MRI of a 19-month-old girl with the chronic-episodic form of the disease showed signal changes in the globi pallidi and the mesencephalic corticospinal tracts, which were hypointense on T1-weighted images and hyperintense on T2 weighted images (57).
Following acute metabolic acidosis, cranial MRI of a 4-month-old girl with the chronic-episodic form of the disease revealed symmetric, bilateral signal-intensity changes in the lentiform nuclei with a symmetric, hyperintense, ring-like appearance bilaterally in the putamen on T1-weighted images (68).
Laboratory studies during decompensation. Metabolic abnormalities during episodes of decompensation may include ketoacidosis, hyperglycemia, hypocalcemia, and hyperammonemia, although the latter is usually mild compared to that in disorders of propionate degradation. Hyperglycemia is most likely due to stress-induced hormonal effects. The combination of ketoacidosis, dehydration, and hyperglycemia has been misjudged as diabetic ketoacidosis (13).
Abnormalities of the hematopoietic system (eg, thrombocytopenia, neutropenia, or pancytopenia) may also occur during metabolic decompensation (58).
Laboratory studies for diagnosis. The best way to distinguish the organic acidemias is through analysis of the urinary nonvolatile organic acid pattern by gas chromatography-mass spectrometry (24; 71; 48). Another complementary and rapid diagnostic technique is the analysis of acylcarnitine profiles by tandem mass spectrometry; the accumulating CoA esters are in equilibrium with their corresponding acylcarnitines, which are easy to analyze in dried blood spots. Mass spectrometry has been adapted to perform newborn screening, leading to early diagnosis and appropriate therapy (11; 37). False-positive results in newborn screening can arise either from antibiotics containing pivalic acid or from pivalic acid derivatives, which are used in the cosmetic industry under the term “neopentanoate” (02; 45; 70; 05).
During metabolic decompensation, the urinary organic acid profile reveals high excretion of isovalerylglycine (2000 to 9000 mmol/mol creatinine), which remains markedly elevated after recompensation (1000 to 3000 mmol/mol creatinine). 3-Hydroxyisovaleric acid is only found elevated during metabolic decompensation.
4-Hydroxyisovaleric, mesaconic acid, methylsuccinic acid, 3-hydroxyisoheptanoic acid, isovalerylglutamic acid, isovalerylglucoronide, isovalerylalanine, and isovalerylsarcosine are minor pathological metabolites detectable in smaller amounts (20 to 300 mmol/mol creatinine) (58).
Other organic acidemias can be differentiated by their specific profiles of urinary organic acids. The acylcarnitine profile in isovaleric aciduria is characterized by high levels of isovaleryl (C5) carnitine, depending on the quantity of oral carnitine administration.
The diagnosis of isovaleric acidemia can be confirmed by enzymatic assay or mutation analysis (29; 48).
Several methods have been successfully used for prenatal diagnosis: genetic variant analysis of IVD genes in amniocytes (59), IVD enzyme activity assay in amniotic or chorionic villi sampling (28), and quantification of the characteristic metabolites such as acylcarnitines and organic acids in amniotic fluid (23; 56; 29; 09). Limitations of prenatal diagnosis by mutation analysis include (1) dependence on the availability of complete genetic information from the proband and parents; and (2) some probands carry only one causative mutation, precluding a precise diagnosis by genetic testing alone (09). Prenatal diagnosis by enzymatic analysis requires cell cultivation, which is troublesome and time-consuming. Also, maternal cell contamination may lead to misdiagnosis (20). Use of mass spectrometry in metabolite analysis provides a fast and convenient method for the prenatal diagnosis (09).
Management
|
• Aspirin is contraindicated in patients with isovaleric acidemia because salicylic acid is a competing substrate for glycine-N-acylase, interfering with isovalerylglycine synthesis. | |
|
• Treatment of patients with isovaleric acidemia has to be supervised by an experienced metabolic center and must continue for life. | |
|
• Special care must be taken to ensure efficient emergency procedures at all times (including travel and holidays) and to monitor carnitine status and dietary management closely, including careful avoidance of overtreatment or malnutrition. | |
|
• Patients should be supplied with an emergency card, letter, or bracelet containing phone numbers and instructions for emergency measure. | |
|
• The primary aim in treating isovaleric acidemia is to prevent the formation of and lower the levels of accumulating toxic metabolites. | |
|
• In patients with isovaleric acidemia, the catabolic pathway is challenged by increased protein intake or increased endogenous protein degradation. | |
|
• The other important therapy principle is to increase the excretion of isovaleric acid as nontoxic glycine and carnitine conjugates. |
Treatment must be supervised by an experienced metabolic center and must continue for life. Special care must be taken to ensure efficient emergency procedures (including travel and holidays) and to always monitor carnitine status and dietary management closely, including careful avoidance of overtreatment or malnutrition (71; 24). Patients should be supplied with an emergency card, letter, or bracelet containing phone numbers and instructions for emergency measures. The team of managing specialists should repeatedly discuss and evaluate the logistics of rational therapeutic measures with both the family and the responsible primary care physician.
Aspirin is contraindicated in patients with isovaleric acidemia because salicylic acid is a competing substrate for glycine-N-acylase, interfering with isovalerylglycine synthesis.
Isovaleric acid is toxic (58); therefore, the primary aim in treating isovaleric acidemia is to both prevent the formation of isovaleric acid and to lower the levels of accumulating toxic metabolites.
The catabolic pathway is challenged by increased protein intake or increased endogenous protein degradation (58). Therefore, total natural protein intake is restricted according to the patient’s leucine tolerance and is adjusted to age-specific requirements for this essential amino acid. The reduction of leucine intake must be carefully monitored to prevent over-restriction. A diet with inadequate leucine intake can impair protein synthesis and lead to catabolic metabolic decompensation, failure to thrive, and additional nutritional insufficiencies (71; 08; 15). To provide a complementary source of the other amino acids, a leucine-free formula is available (58; 29).
Dietary practice in Europe has been systematically studied and has been found to vary considerably among centers (52). In 2014, a quick-reference, web-based guide was published by E-IMD, but universal treatment recommendations are needed (14).
The other important principle of therapy is to increase the excretion of isovaleric acid as nontoxic glycine and carnitine conjugates (58). Glycine is conjugated to isovaleric acid to form isovalerylglycine by glycine N-acyltransferase (glycine-N-acylase). Normal tissue concentrations of glycine are already lower than the Km concentrations for optimal enzyme functioning and tend to decrease further during metabolic decompensation (58). Therefore, it is important to ensure sufficient glycine levels to allow optimal detoxification. Therapeutic guidelines recommend a dosage of 150 (to at most 250) mg/kg per day of glycine while the patient is stable and under protein restriction (49; 01). The dosage can be augmented during metabolic crises. Glycine supplementation of more than 250 mg/kg/day under stable conditions may reduce isovalerylglycine production (49).
In contrast, in metabolic crises, when isovaleric acid accumulation is increased, glycine supplements to 600 mg/kg/day will increase isovalerylglycine production (49). Isovaleric acidemia is related not only to the extent of impaired isovaleryl-CoA dehydrogenase but also to the ability to detoxify accumulated isovaleryl CoA to isovalerylglycine (49).
Many patients with isovaleric acidemia show low levels of total carnitine in plasma and a high percentage of esterified carnitines in plasma and urine (58; 29). This results from enzymatic production of isovalerylcarnitine by carnitine acetyltransferase and the subsequent loss of isovalerylcarnitine in the urine. Consequently, carnitine stores may become exhausted, resulting in severe secondary metabolic consequences. Therefore, L-carnitine should be supplemented in doses of 40 to 100 mg/kg to ensure high-normal free carnitine levels in plasma.
It is difficult to determine whether treatment with glycine is more effective than treatment with carnitine because all reports lack a common study protocol, do not have adequate sample size, and do not control for the patients’ age, diet, and medication dosage. As a first estimation, excretion of isovaleric acid via glycine is quantitatively more important, together with a moderate restriction of leucine intake (58). Treatment with L-carnitine prevents carnitine deficiency and provides a second detoxification pathway (58). A treatment recommendation from E-IMD recommends L-carnitine in combination with L-glycine in metabolically severe phenotypes (14).
During acute decompensation, isovaleric acidemia must be treated like other organic acidemias. Measures include increased provision of energy via oral, nasogastric, or intravenous routes by 20% to 100% above the recommended daily requirements using carbohydrate (eg, glucose or dextrose 20% orally or glucose intravenously) and fat (intralipid 20%). Soluble insulin should be provided to avoid hyperglycemia and to support intracellular glucose uptake. The intake of natural protein should be stopped for 24 to 48 hours and is then reintroduced gradually as tolerated (24). Additional specific treatment recommendations include augmented doses of glycine and high-dose L-carnitine (58). N-carbamylglutamate (carglumic acid) has been used to overcome neonatal hyperammonemia due to inhibition of N-acetylglutamate synthetase by isovaleryl-CoA, which is analogous to the use of this substance in other organic acidemias (27; 04).
It is unclear whether patients carrying the common mutation (A282V, 932C> T) associated with a biochemically and clinically mild phenotype require any treatment. Close observation during periods of metabolic stress and carnitine supplementation if free carnitine concentrations are very low seems reasonable (64).
Outcomes
Early diagnosis is crucial. If treatment can be initiated before a first severe metabolic decompensation, the patient’s prognosis is significantly improved. Individuals who receive treatment before becoming symptomatic usually have normal long-term psychomotor development (37; 19).
In 24 individuals with classic (early-onset) isovaleric acidemia, newborn screening and early institution of therapy prevented untimely death, except in one individual with lethal neonatal sepsis, but did not completely prevent single or recurrent metabolic decompensations (46). IQ of individuals with isovaleric acidemia was generally in the normal range (albeit on the low side; mean ± SD, 91 ± 10) but was significantly below that of the reference population and was even lower in individuals with severe neonatal decompensations (IQ 79 ± 7) compared to those without crises (IQ 95 ± 8). In contrast, individuals with mild (later onset) isovaleric acidemia had excellent neurocognitive outcomes (IQ 106 ± 16), normal school placement, a benign disease course with no metabolic decompensations, and a normal hospitalization rate. In the later-onset group, metabolic maintenance therapy did not appear to alter the disease course (or benefit the patients). These findings indicate that a one-size-fits-all treatment regimen is not likely to benefit a large proportion of cases with milder phenotypes (46). Consequently, "harmonized stratified therapeutic concepts are urgently needed" (46).
Patients identified by newborn screening who carry the common mutation (A282V, 932C> T) are usually asymptomatic and most likely do not need treatment. Siblings of these individuals who have the same genotype remain asymptomatic during episodes of febrile illnesses without any specific treatment (12; 64; 37).
Special considerations
Pregnancy
In women with isovaleric acidemia, the outcomes for both mother and child seem to be good (62). However, close monitoring of sufficient protein and energy intake is important. Catabolic stress has to be anticipated during labor and involution of the uterus and may require intravenous glucose treatment (62).
Anesthesia
Patients are at risk for metabolic decompensation by catabolism induced by fasting, anesthesia, or a surgical procedure. It is essential to meet increased energy requirements in these situations by intravenous administration of dextrose (24). Augmented doses of glycine and high-dose L-carnitine should be provided. No information is available about particular side effects of drugs normally used to induce anesthesia in patients with isovaleric acidemia.
Media
References
- 01
- Blau N, Hoffmann GF, Leonard J, Clarke JTR, editors. Physician’s guide to the treatment and follow-up of metabolic diseases. Berlin, Heidelberg, New York: Springer, 2006.
- 02
- Boemer F, Schoos R, de Halleux V, Kalenga M, Debray FG. Surprising cause of C5-carnitine false positive results in newborn screening. Mol Genet Metab 2014;111(1):52-4. PMID 24291264
- 03
- Budd MA, Tanaka K, Holmes LB, Efron ML, Crawford JD, Isselbacher KJ. Isovaleric acidemia: clinical features of a new genetic defect of leucine metabolism. N Engl J Med 1967;277:321-7. PMID 4378266
- 04
- Burlina A, Bettocchi I, Biasucci G, et al. Long-term use of carglumic acid in methylmalonic aciduria, propionic aciduria and isovaleric aciduria in Italy: a qualitative survey. Eur Rev Med Pharmacol Sci 2022;26(14):5136-43. PMID 35916811
- 05
- Carling RS, Hedgethorne K, Chakrapani A, et al. Retrospective review of positive newborn screening results for isovaleric acidemia and development of a strategy to improve the efficacy of newborn screening in the UK. Int J Neonatal Screen 2024;10(1):24. PMID 38535128
- 06
- Chen W, Miao C, Li Y, et al. A case report of a novel isovaleryl-CoA dehydrogenase gene mutation in a Chinese family with isovaleric acidemia. Clin Lab 2023;69(9). PMID 37702673
- 07
- Dercksen M, Duran M, Iljilst L, et al. Clinical variability of isovaleric acidemia in a genetically homogenous population. J Inherit Metab Dis 2012;35(6):1021-9. PMID 22350545
- 08
- Dercksen M, Kulik W, Mienie LJ, et al. Polyunsaturated fatty acid status in treated isovaleric acidemia patients. Eur J Clin Nutr 2016;70(10):1123-6. PMID 27329611
- 09
- Ding S, Liang L, Qiu W, et al. Prenatal diagnosis of isovaleric acidemia from amniotic fluid using genetic and biochemical approaches. Front Genet 2022;13:898860. PMID 35846131
- 10
- Dubiel B, Dabrowski C, Wetts R, Tanaka K. Complementation studies of isovaleric acidemia and glutaric aciduria type II using cultured skin fibroblasts. J Clin Invest 1983;72:1543-52. PMID 6630517
- 11
- Ensenauer R, Fingerhut R, Maier EM, et al. Newborn screening for isovaleric acidemia using tandem mass spectrometry: data from 1.6 million newborns. Clin Chem 2011;57(4):623-6.** PMID 21335445
- 12
- Ensenauer R, Vockley J, Willard JM, et al. A common mutation is associated with a mild, potentially asymptomatic phenotype in patients with isovaleric acidemia diagnosed by newborn screening. Am J Hum Genet 2004;75(6):1136-42. PMID 15486829
- 13
- Erdem E, Cayonu N, Uysalol E, Yildirmak ZY. Chronic intermittent form of isovaleric acidemia mimicking diabetic ketoacidosis. J Pediatr Endocrinol Metab 2010;23(5):503-5. PMID 20662350
- 14
- European Registry and Network For Intoxication-Type Metabolic Diseases. Isovaleric aidemia: Quick reference guide. Accessed June 6, 2022. https://www.e-imd.org/files/medias/files/recommendations/IVA%20guideline_Quick%20reference%20guide_Ensenauer_201408.pdf. 2014.
- 15
- Evans M, Truby H, Boneh A. The relationship between dietary intake, growth, and body composition in inborn errors of intermediary protein metabolism. J Pediatr 2017:188:163-72. PMID 28629683
- 16
- Feinstein JA, O’Brien K. Acute metabolic decompensation in an adult patient with isovaleric acidemia. South Med J 2003;96(5):500-3. PMID 12911192
- 17
- Finocchiaro G, Ito M, Tanaka K. Purification and properties of short chain acyl CoA, medium chain acyl CoA and isovaleryl CoA dehydrogenases from human liver. J Biol Chem 1987;262:7982-9. PMID 3597357
- 18
- Gancheva S, Caspari D, Bierwagen A, et al. Cardiometabolic risk factor clustering in patients with deficient branched-chain amino acid catabolism: a case-control study. J Inherit Metab Dis 2020;43(5):981-93. PMID 32118306
- 19
- Grunert SC, Wendel U, Lindner M, et al. Clinical and neurocognitive outcome in symptomatic isovaleric acidemia. Orphanet J Rare Dis 2012;7:9.** PMID 22277694
- 20
- Hasegawa M, Takehara K, Sato S. Scleroderma. Nihon Rinsho 2005;63 Suppl 5: 295-5. PMID 15954365
- 21
- Heringer J, Valayannopoulos V, Lund AM, et al. Impact of age at onset and newborn screening on outcome in organic acidurias. J Inherit Metab Dis 2016;39:341–53. PMID 26689403
- 22
- Hertecant JL, Ben-Rebeh I, Marah MA, et al. Clinical and molecular analysis of isovaleric acidemia patients in the United Arab Emirates reveals remarkable phenotypes and four novel mutations in the IVD gene. Eur J Med Genet 2012;55(12):671-6. PMID 22960500
- 23
- Hine DG, Hack AM, Goodman SI, Tanaka K. Stable isotope dilution analysis of isovalerylglycine in amniotic fluid and urine and its application for the prenatal diagnosis of isovaleric acidemia. Pediatr Res 1986;20(3):222-6. PMID 3703611
- 24
- Hoffmann GF, Zschocke J, Nyhan WL. Inherited Metabolic Diseases – A practical approach. Heidelberg: Springer, 2016.
- 25
- Ibarra-Gonzalez I, Fernández-Lainez C, Guillén-López S, et al. Molecular analysis using targeted next generation DNA sequencing and clinical spectrum of Mexican patients with isovaleric acidemia. Clin Chim Acta 2020;501:216-21. PMID 31707166
- 26
- Joshi SN, Venugopalan P. Clinical characteristics of neonates with inborn errors of metabolism detected by tandem MS analysis in Oman. Brain Dev 2007;29(9):543-6. PMID 17314022
- 27
- Kasapkara CS, Ezgu FS, Okur I, Tumer L, Biberoglu G, Hasanoglu A. N-carbamylglutamate treatment for acute neonatal hyperammonemia in isovaleric acidemia. Eur J Pediatr 2011;170(6):799-801. PMID 21207059
- 28
- Kleijer WJ, van der Kraan M, Huijmans JG, van den Heuvel CM, Jakobs C. Prenatal diagnosis of isovaleric acidaemia by enzyme and metabolite assay in the first and second trimesters. Prenat Diagn 1995;15(6):527-33. PMID 7659686
- 29
- Knerr I, Vockley J, Gibson KM. Disorders of leucine, isoleucine, and valine metabolism. In: Blau N, Duran M, Gibson KM, Dionisi-Vici C, editors. Physician’s guide to the diagnosis, treatment, and follow-up of inherited metabolic diseases. Heidelberg, New York: Springer, 2014:103-41.
- 30
- Kolker S, Valayannopoulos V, Burlina AB, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. J Inherit Metab Dis 2015;38(6):1059-74. PMID 25875216
- 31
- Kraus JP, Matsubara Y, Barton D, et al. Isolation of cDNA clones coding for rat isovaleryl-CoA dehydrogenase and assignment of the gene to human chromosome 15. Genomics 1987;1:264-9. PMID 3446585
- 32
- Kühn S, Williams ME, Dercksen M, Sass JO, van der Sluis R. The glycine N-acyltransferases, GLYAT and GLYATL1, contribute to the detoxification of isovaleryl-CoA - an in-silico and in vitro validation. Comput Struct Biotechnol J 2023;21:1236-48. PMID 36817957
- 33
- Lee HH, Lee RS, Lai CK, et al. A novel duplication at the putative DNA polymerase alpha arrest site and a founder mutation in Chinese in the IVD gene underlie isovaleric acidaemia. Hong Kong Med J 2010;16(3):219-22. PMID 20519759
- 34
- Lehnert W, Schenck W, Niederhoff H. Isovaleric acidemia kombiniert mit hypertrophischer Pylorusstenose. Klin Padiatr 1979;191(5):477-82. PMID 574579
- 35
- Li Y, Shen M, Jin Y, Liu Y, et al Eight novel mutations detected from eight Chinese patients with isovaleric acidemia. Clin Chim Acta 2019;498:116-21. PMID 31442447
- 36
- Lin Y, Chen D, Peng W, et al. Newborn screening for isovaleric acidemia in Quanzhou, China. Clin Chim Acta 2020;509:25-9. PMID 32505769
- 37
- Lindner M, Gramer G, Haege G, et al. Efficacy and outcome of expanded newborn screening for metabolic diseases – report of 10 years from South-West Germany. Orphanet J Rare Dis 2011;6:44. PMID 21689452
- 38
- Loots DT. Abnormal tricarboxylic acid cycle metabolites in isovaleric acidaemia. J Inherit Metab Dis 2009;32(3):403-11. PMID 19343532
- 39
- Loots DT, Mienie LJ, Erasmus E. Amino-acid depletion induced by abnormal amino-acid conjugation and protein restriction in isovaleric acidemia. Eur J Clin Nutr 2007;61(11):1323-7. PMID 17299485
- 40
- Lorek AK, Penrice JM, Cady EB, et al. Cerebral energy metabolism in isovaleric acidemia. Arch Dis Child Fetal Neonatal Ed 1996;74(3):F211-3. PMID 8777688
- 41
- Mantadakis E, Chrysafis I, Tsouvala E, Evangeliou A, Chatzimichael A. Acute pancreatitis with rapid clinical improvement in a child with isovaleric acidemia. Case Rep Pediatr 2013;2013:721871. PMID 23431490
- 42
- Marquez-Caraveo ME, Ibarra-González I, Rodríguez-Valentín R, et al. Brief report: delayed diagnosis of treatable inborn errors of metabolism in children with autism and other neurodevelopmental disorders. J Autism Dev Disord 2021;51(6):2124-31. PMID 32880084
- 43
- Matsubara Y, Ito M, Glasssberg R, Satyabhama S, Ikeda Y, Tanaka K. Nucleotide sequence of messenger RNA encoding human isovaryl coenzyme A dehydrogenase and its expression in isovaleric acidemia fibroblasts. J Clin Invest 1990;85:1058-64. PMID 2318964
- 44
- Moorthie S, Cameron L, Sagoo GS, Bonham JR, Burton H. Systematic review and meta-analysis to estimate the birth prevalence of five inherited metabolic diseases. J Inherit Metab Dis 2014;37(6):889-98. PMID 25022222
- 45
- Murko S, Aseman AD, Reinhardt F, et al. Neonatal screening for isovaleric aciduria: Reducing the increasingly high false-positive rate in Germany. JIMD Rep 2022;64(1):114-20. PMID 36636590
- 46
- Mutze U, Henze L, Gleich F, et al. Newborn screening and disease variants predict neurological outcome in isovaleric aciduria. J Inherit Metab Dis 2021;44(4):857-70. PMID 33496032
- 47
- Mutze U, Henze L, Schröter J, et al. Isovaleric aciduria identified by newborn screening: strategies to predict disease severity and stratify treatment. J Inherit Metab Dis 2023;46(6):1063-77. PMID 37429829
- 48
- Mutze U, Reischl-Hajiabadi A, Kölker S. Classic isovaleric acidemia. In: Adam MP, Feldman J, Mirzaa GM, et al, editors. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle, 2024. PMID 38484105
- 49
- Naglak M, Salvo R, Madsen K, Dembure P, Elsas L. The treatment of isovaleric acidemia with glycine supplement. Pediatr Res 1988;24(1):9-13. PMID 3137519
- 50
- Newman CG, Wilson BD, Callaghan P, Young L. Neonatal death associated with isovaleric acidaemia. Lancet 1967;2(7513):439-42. PMID 4166104
- 51
- Parimoo B, Tanaka K. Structural organisation of the human isovaleryl-CoA dehydrogenase gene. Genomics 1993;582-90. PMID 8468053
- 52
- Pinto A, Daly A, Evans S, et al. Dietary practices in isovaleric acidemia: a European survey. Mol Genet Metab Rep 2017;12:16-22. PMID 28275552
- 53
- Rhead WJ, Tanaka K. Demonstration of a specific mitochondrial isovaleryl-CoA dehydrogenase deficiency in fibroblasts from patients with isovaleric acidemia. Proc Natl Acad Sci USA 1980;77:580-3.** PMID 6928646
- 54
- Salmi H, Leonard JV, Lapatto R. Patients with organic acidemias have an altered thiol status. Acta Paediatr 2012;101(11):505-8. PMID 22849335
- 55
- Sezer T, Balci O. Infantile spasms during acute metabolic decompensation in an infant with isovaleric acidemia. J Clin Neurol 2016;12(3):376-7. PMID 27165427
- 56
- Shigematsu Y, Kikawa Y, Sudo M, Kanaoka H, Fujioka M, Dan M. Prenatal diagnosis of isovaleric acidemia by fast atom bombardment and tandem mass spectrometry. Clin Chim Acta 1991;203(2-3):369-74. PMID 1777996
- 57
- Sogut A, Acun C, Aydin K, Tomsac N, Demirel F, Aktuglu C. Isovaleric acidemia: cranial CT and MRI findings. Pediatr Radiol 2004;34(2):160-2. PMID 14534755
- 58
- Sweetman L, Williams J. Branched chain organic acidurias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. Eighth ed. New York: McGraw Hill, 2001:2125-63.
- 59
- Tanacan A, Gurbuz BB, Aydin E, Erden M, Coskun T, Beksac MS. Prenatal diagnosis of organic acidemias at a tertiary center. Balkan J Med Genet 2019;22(1):29-34. PMID 31523617
- 60
- Tanaka K. Isovaleric acidemia: personal history, clinical survey and study of the molecular basis. Prog Clin Biol Res 1990;321:273-90. PMID 2326294
- 61
- Tanaka K, Budd MA, Efron ML, Isselbacher KJ. Isovaleric acidemia: a new genetic defect of leucine metabolism. Proc Natl Acad Sci 1966;56:236-42.** PMID 5229850
- 62
- Tuncel AT, Boy N, Morath MA, Hörster F, Mütze U, Kölker S. Organic acidurias in adults: late complications and management. J Inherit Metab Dis 2018;41(5):765-76.** PMID 29335813
- 63
- Vatanavicharn N, Liammongkolkul S, Sakamoto O, Sathienkijkanchai A, Wasant P. Phenotypic and mutation spectrums of Thai patients with isovaleric acidemia. Pediatr Int 2011;53(6):990-4. PMID 22004070
- 64
- Vockley J, Ensenauer R. Isovaleric academia: New aspects of genetic and phenotypic heterogeneity. Am J Hum Genet (seminars in medical genetics) 2006;142C:95-103.** PMID 16602101
- 65
- Vockley J, Nagao M, Parimoo B, Tanaka K. The variant human isovaleryl-CoA dehydrogenase gene responsible for type II isovaleric acidemia determines an rNA splicing error, leading to deletion of the entire second coding exon and the production of a truncated precursor protein that interacts poorly with mitochondrial import receptors. J Biol Chem 1992;267:2494-501. PMID 1310317
- 66
- Vockley J, Parimoo B, Tanaka K. Molecular characterization of four different classes of mutations in isovaleryl-CoA dehydrogenase gene responsible for isovaleric acidemia. Am J Hum Genet 1991;49:147-57. PMID 2063866
- 67
- Vockley J, Rogan PK, Anderson BD, et al. Exon skipping in IVD RNA processing in isovaleric acidemia caused by point mutations in the coding region of the IVD gene. Am J Hum Genet 2000;66:356-67. PMID 10677295
- 68
- Wani NA, Qureshi UA, Jehangir M, Ahmad K, Hussain Z. Atypical MR lenticular signal change in infantile isovaleric acidemia. Indian J Radiol Imaging 2016;26(1):131-4. PMID 27081237
- 69
- Wasant P, Liammongkolkul S, Kuptanon C, Vatanavicharn N, Sathienkijakanchai A, Shinka T. Organic acid disorders detected by urine organic acid analysis: twelve cases in Thailand over three-year experience. Clin Chim Acta 2008;392(1-2):63-8. PMID 18339316
- 70
- Zaunseder E, Mütze U, Garbade SF, et al. Machine learning methods improve specificity in newborn screening for isovaleric aciduria. Metabolites 2023;13(2):304. PMID 36837923
- 71
- Zschocke J, Hoffmann GF. Vademecum Metabolicum: Manual of Metabolic Paediatrics. 3rd edition. Stuttgart: Schattauer Verlag, 2011.
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Douglas J Lanska MD MS MSPH
Dr. Lanska of the University of Wisconsin School of Medicine and Public Health and the Medical College of Wisconsin has no relevant financial relationships to disclose.
See Profile
Former Authors
- Friederike Hoerster MD
- Georg F Hoffmann MD
- Jennifer Friedman MD
Patient Profile
- Age range of presentation
-
- 0 month to 64 years
- Sex preponderance
-
- male=female
- Heredity
-
- heredity may be a factor
- autosomal recessive
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-10
-
- Isovaleric acidemia: E71.1
- ICD-11
-
- Classical organic aciduria: 5C50.E0
- OMIM
-
- Isovaleric acidemia: #243500
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Stroke & Vascular Disorders
White matter abnormalities in the brain
Sep. 12, 2024
-
Neurogenetic Disorders
Hypermethioninemia
Sep. 12, 2024
-
Neurogenetic Disorders
POLG-related mitochondrial disorders
Sep. 12, 2024
-
Neurogenetic Disorders
Multiple acyl-CoA dehydrogenase deficiency
Sep. 12, 2024
-
Neurogenetic Disorders
Medium-chain acyl-CoA dehydrogenase deficiency
Sep. 12, 2024
-
Neurogenetic Disorders
Long-chain fatty acid oxidation defects
Sep. 12, 2024
-
Neurogenetic Disorders
Nonketotic hyperglycinemia
Sep. 03, 2024